IAVI collaboration update (2839E)
April 05 2011 - 2:00AM
UK Regulatory
TIDMLPX
RNS Number : 2839E
Lipoxen PLC
05 April 2011
5 April 2011
Lipoxen plc
('Lipoxen' or the 'Company')
IAVI collaboration update
Lipoxen (AIM: LPX.L), a bio-pharmaceutical company specialising
in the development of high-value differentiated biological,
vaccines and siRNA delivery, announces that is has agreed an
extension of the existing research agreement with the International
Aids Vaccine Initiative (IAVI), the world's leading AIDS vaccine
organization.
Based on data generated during the research phase of the
original agreement, Lipoxen and IAVI have identified a vaccine
formulation that, when used in a relevant preclinical model,
induced antibodies which subsequently neutralised a number of
different HIV strains when tested in the laboratory.
IAVI have extended the agreement which will now run until 30
September 2011. This will allow Lipoxen to create advanced versions
of the candidate formulation and IAVI to undertake a repeat of the
immunisation study to assess the efficacy of the refined
vaccine.
Subject to the final results, Lipoxen and IAVI will jointly
negotiate terms for the further development of any promising
vaccine candidate.
Commenting on the extension, M. Scott Maguire, Chief Executive
Officer of Lipoxen, said:
"The extension is a positive step and reflects the good antibody
responses to our formulations. With more than 7,100 people a day
infected with HIV there is strong demand for safe and effective
vaccines for HIV and we hope that the extension will help us and
IAVI take a step closer to developing a refined vaccine formulation
that meets this need."
For further information, please contact:
Lipoxen plc +44 (0)20 7389 5015
M. Scott Maguire, Chief Executive
Officer
Singer Capital Markets (nominated
adviser) +44 (0)20 3205 7500
Jeff Keating / Claes Spang
Walbrook PR Ltd +44 (0)20 7933 8780
Paul McManus (Media Enquiries) Mob: 07980 541 893
paul.mcmanus@walbrookpr.com
Paul Cornelius (Investor Enquiries) Mob: 07866 384 707
paul.cornelius@walbrookir.com
About Lipoxen
Lipoxen plc is a biopharmaceutical company focused on the
development of new and improved biologic drugs and vaccines.
Lipoxen has three proprietary patented technology platforms:
1) PolyXen - for extending the efficacy and half life of
biologic drugs
2) ImuXen - for creating new vaccines and improving existing
vaccines
3) SiRNAblate - for the delivery of siRNA
Lipoxen's technology is designed to improve the efficacy,
safety, stability, biological half-life and immunologic
characteristics of its products.
Lipoxen has multiple drug and vaccine programmes in development.
Two products are in clinical development, SuliXen, a long acting
insulin and ErepoXen, a long-acting erythropoietin (EPO). Lipoxen's
preclinical pipeline includes vaccines against HIV, multiple
sclerosis and influenza and an exclusive license deal with Baxter
Healthcare for blood coagulation drugs.
The Company has a low-risk business model and out-licenses its
proprietary technologies to biopharmaceutical companies that have
strong manufacturing and marketing capabilities. Lipoxen currently
has commercial agreements with some of the world's leading
biotechnology and pharmaceutical companies including Baxter,
Schering-Plough, the Serum Institute of India Limited, Genentech,
and Genzyme. Furthermore, Baxter, the Company's third largest
shareholder, and management led the GBP2.9 million fundraising that
the Company announced in May 2009. This fundraising was followed up
by a GBP1.2 million placing in April 2010 which was led by the
Company's management team.
Lipoxen, which was founded in 1997, trades on the AIM Market of
the London Stock Exchange under the ticker symbol LPX. More
information can be found at the Company's website:
www.lipoxen.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBLGDSRSGBGBS
Lipoxen (LSE:LPX)
Historical Stock Chart
From Apr 2024 to May 2024
Lipoxen (LSE:LPX)
Historical Stock Chart
From May 2023 to May 2024
